edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Basilea Pharmaceutica
Basilea Pharmaceutica is focused on treating infectious diseases; its marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA antibiotic). In late 2023, it expanded its pipeline to include fosmanogepix, BAL2062 and tonabacase. In January 2024, it acquired the preclinical LptA inhibitor antibiotics programme from Spexis.
Basilea Pharmaceutica — 2 videos in collection
Basilea Pharmaceutica, a Switzerland-based commercial-stage biotech company, specialises in developing innovative treatments for infectious diseases. In this video, CEO David Veitch highlights the urgent need for new therapies to combat severe bacterial and fungal infections. He also discusses the company’s global commercial strategy and the compelling investment opportunity it presents. With a market capitalisation of CHF540m, Basilea is positioned at the forefront of addressing critical healthcare challenges.
Listen on your preferred podcast player below:
About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.
Get access to the very latest content matched to your personal investment style.